Share

EORTC is supporting Clinical Trials Day on 20th May

Since 2014, Clinical Trials Day celebrates achievements from the clinical research community and sheds light on the importance of continuous progress in treatment and care for the benefit of patients.  

At EORTC, we dedicate our work to patients and all those affected by cancer. As Europe’s leading cancer multidisciplinary clinical research organisation, we unite research experts worldwide to define better treatments for cancer patients and improve their survival and quality of life.   

In the past 60 years, EORTC has entered over 210 707 patients in practice-changing clinical trials across various tumour types, including brain, breast, prostate, melanoma, head and neck, and soft tissue sarcoma. In 2022 only, 22 studies were open to patient entry, bringing science and knowledge to patients for therapeutic improvement.  

The Clinical Trials Day is a unique opportunity to enhance the value of independent clinical cancer research for multidisciplinary therapeutic improvement.
– Dr. Denis Lacombe, EORTC CEO.

This year, we would like to dedicate this day to pragmatic clinical trials.  There is a need to conduct independent pragmatic clinical trials studying the optimal way to use the drugs in a real-life setting. This can improve patients’ quality of life and also the sustainability of healthcare systems. 

We remain devoted to being “the place to meet” for oncology in Europe and beyond, bringing together disease experts, representatives of all disciplines, translational scientists, and other stakeholders to address the multifaceted challenges that lie ahead. This is the fundamental reason why EORTC exists and why our network plays such a vital role in driving progress and innovation in oncology research and therapy. 

Back to news list

Related News

  • New study confirms a key quality of life tool can be used with adolescents with cancer

  • “Changing practice, improving lives”: EORTC publishes its Annual Report 2025

  • This Clinical Trials Day, EORTC announces the upcoming Summit for Clinical Cancer Research

  • Multinational study provides new evidence for the value of response-adapted, personalised treatment in Hodgkin lymphoma

  • EORTC’s presence at ESTRO 2026

  • Independent, academic cancer trials are vital to improve patient outcomes worldwide

  • EORTC Imaging Group Becomes the Diagnostic and Therapeutic Imaging Group

  • Investing in the future of cancer research; EORTC’s Young and Early Career investigator Network shows its value

  • In Memoriam of Martine Van Glabbeke (1951-2026)

  • PEACE-3 trial demonstrates significant overall survival benefit in patients with metastatic castration-resistant prostate cancer with bone metastases